Corvus Pharmaceuticals, Inc.
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$15.3M
- Total assets
- $71.1M
- Market cap
- $935.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $43.0M
- Operating income
- -$43.0M
- Income tax
- $0
- Net income
- -$15.3M
- EPS (basic)
- $-0.19
- EPS (diluted)
- $-0.53
Balance sheet
- Total assets
- $71.1M
- Current assets
- $58.2M
- Total liabilities
- $9.9M
- Current liabilities
- $9.4M
- Shareholders’ equity
- $61.2M
Cash flow
- Operating cash flow
- -$32.8M
- Investing cash flow
- -$7.8M
- Financing cash flow
- $36.4M
- Net cash flow
- -$4.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $935.1M
- EPS (diluted)
- $-0.53
- Shares outstanding
- 83.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 23, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $15.3M.
- Trading 56% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Corvus Pharmaceuticals, Inc..
Write a review
News about Corvus Pharmaceuticals, Inc.
News & sentiment via Polygon.io
